- Synthesis of modified baccatins via an oxidation-reduction protocol
-
(12R)-7-trietylsilyl-11-dihydro-10-deacetylbaccatin III (2), -deacetylbaccatin III (4) and the 7,8-seco baccatin III (5a) were synthesized from 10-deacetylbaccatin III via an oxidation-reduction protocol.
- Appendino, Giovanni,Jakupovic, Jasmin,Cravotto, Giancarlo,Enriu, Renata,Varese, Marcella,Bombardelli, Ezio
-
-
Read Online
- New and effective synthesis of 7-triethylsilylbaccatin III from 7β,13α-bistriethylsiloxy-1β,2α,10β-trihydroxy-9-oxo- 4(20),11-taxadiene
-
7β,13α-Bistriethylsiloxy-1β,2α,10β-trihydroxy -9- oxo-4(20), 11-taxadiene (2), derived from 10-deacetylbaccatin III via degradation of oxetane ring, was conveniently converted into 7-triethylsilylbaccatin III (1) by way of a new and effective method for constructing oxetane ring. Thus, the synthesis of a precursor of taxol from novel taxoid 2 was accomplished.
- Shiina, Isamu,Saitoh, Masahiro,Nishimura, Koji,Saitoh, Katsuyuki,Mukaiyama, Teruaki
-
-
Read Online
- A facile one-pot synthesis of 7-triethylsilylbaccatin III
-
A one-pot synthesis of 7-triethylsilylbaccatin III has been delineated. The reaction can easily be extended for the preparation of analogs of baccatin III.
- Baloglu, Erkan,Miller, Michael L.,Cavanagh, Emily E.,Marien, Tracy P.,Roller, Elizabeth E.,Chari, Ravi V. J.
-
-
Read Online
- Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis
-
A noncleavable paclitaxel (PTX) and N-acetylmuramyl-l-alanyl-d-isoglutamine (MDP) derivative conjugate, 22 (DY-16-43), and its analogues were prepared and characterized as antagonists of NOD2 signaling. This conjugate enhanced the antitumor and antimetastatic efficacy of PTX in Lewis lung carcinoma (LLC) tumor-bearing mice. This work first describes a molecular strategy that enables the sensitization of a chemotherapeutic response via antagonizing NOD2 inflammatory signaling and suggests NOD2 antagonist as potential adjunct in treating non-small-cell lung cancer (NSCLC).
- Dong, Yi,Wang, Suhua,Wang, Chunting,Li, Zihua,Ma, Yao,Liu, Gang
-
-
Read Online
- Total synthesis of Taxol. 1. Retrosynthesis, degradation, and reconstitution
-
A successful strategy for the enantioselective synthesis of the natural stereoisomer of Taxol (1) has been developed. This strategy utilized the convergent assembly of Taxol's central eight-membered B ring from preformed synthons for rings A (10) and C (9) followed by late introduction of the D ring and side chain. Degradative studies confirmed the viability of certain crucial manipulations including oxidation of the C13 position (35 → 3) and regioselective introduction of the C1-hydroxyl, C2-benzoyloxy moiety (29 → 31). Additionally, a convenient method for the large-scale production of 29, a derivative useful for C2 analog production, was developed.
- Nicolaou,Nantermet,Ueno,Guy,Couladouros,Sorensen
-
-
Read Online
- β-Selective Aroylation of Activated Alkenes by Photoredox Catalysis
-
Late-stage synthesis of α,β-unsaturated aryl ketones remains an unmet challenge in organic synthesis. Reported herein is a photocatalytic non-chain-radical aroyl chlorination of alkenes by a 1,3-chlorine atom shift to form β-chloroketones as masked enones
- Lei, Zhen,Banerjee, Arghya,Kusevska, Elena,Rizzo, Eric,Liu, Peng,Ngai, Ming-Yu
-
supporting information
p. 7318 - 7323
(2019/04/30)
-
- Fluorinated taxane compound, preparation method therefor and application of fluorinated taxane compound
-
The invention discloses a fluorinated taxane compound, a preparation method therefor and an application of the fluorinated taxane compound. The compound has a structural general formula represented bya formula I. Proven by pharmacological experiments, compared with paclitaxel, a series of fluorinated taxane derivatives synthesized by the method have cytotoxicity superior to that of the paclitaxelto a multidrug-resistant human mammary cancer cell line MCF-7/Adr and an ovarian cancer cell line NCI/Adr and represent cytotoxicity superior to that of the paclitaxel to a colon cancer cell line HCT-116 with overexpressed neoplasm stem cells.
- -
-
Paragraph 0048; 0085-0089
(2019/08/30)
-
- Preparation method of taxane compound and intermediate of taxane compound
-
The invention provides a preparation method of a taxane compound and an intermediate of the taxane compound. The preparation method of a TPI-287 intermediate A starts with a starting step of a raw material 10-deacetylbaccatin III (also named as 10-DAB), a
- -
-
Paragraph 0155; 0156; 0157; 0158; 0159; 0160
(2017/08/29)
-
- Preparation method of 10,13-two-branched-chain-taxol
-
The invention discloses a preparation method of 10,13-two-branched-chain-taxol. The preparation method comprises the following steps: taking 10-Dab as a raw material; protecting 7-hydroxyl by using a silyl ether protecting agent; simultaneously condensing
- -
-
Paragraph 0028; 0034; 0039
(2017/12/14)
-
- Methods for preparing semi-synthetic paclitaxel and intermediate thereof
-
The invention relates to methods for preparing semi-synthetic paclitaxel and an intermediate thereof. The method for preparing the semi-synthetic paclitaxel comprises the following steps: dissolving 10-DABIII (10-deacetylbaccatinIII) into pyridine, protecting hydroxyl on position-7 carbon on the 10-DABIII with triethyl silicyl to obtain an intermediate I, acetylating hydroxyl on position-10 carbon of the intermediate I to obtain an intermediate II, reacting the intermediate II, a side-chain radical compound and 4-dimethylaminopyridine in an organic solvent to prepare an intermediate III, and reacting the intermediate III with trifluoroacetic acid under an acidic condition to obtain a crude paclitaxel product. The preparation methods are simple and easy for industrialization; the active hydroxyl of the raw material 10-DABIII is effectively protected, so that fewer byproducts are finally generated, and a prepared paclitaxel product has high molar yield of 70 to 81 percent and high paclitaxel purity of 99.5 to 99.9 percent; the residual rate of the raw material in the steps of synthesizing the intermediate II and synthesizing the paclitaxel is low, side reactions are reduced, and the raw material is high in reaction selectivity and utilization rate; the product can be directly used as a raw material for the medical field of treatment of ovarian cancer, breast cancer and the like.
- -
-
Paragraph 0051; 0052; 0065; 0066
(2017/08/28)
-
- Kaba he of the intermediate compounds (by machine translation)
-
The present invention relates to intermediate compounds of Kabbah, in particular for the preparation of the intermediate compound he Kabbah 6, preparation method thereof, and he Kabbah for preparing the compound of the method. Intermediates to of the present invention the process of preparing kaba he races, in each step of the reaction time is greatly shortened, the reaction yield is greatly improved, greatly reduces the cost of synthesizing of Kabbah. (by machine translation)
- -
-
Paragraph 0139 - 0145
(2017/05/25)
-
- Ferrocenyl Paclitaxel and Docetaxel Derivatives: Impact of an Organometallic Moiety on the Mode of Action of Taxanes
-
A series of ferrocenyl analogues and derivatives of paclitaxel and docetaxel were synthesised and assayed for their antiproliferative/cytotoxic effects, impact on the cell cycle distribution and ability to induce tubulin polymerisation. The replacement of the 3′-N-benzoyl group of paclitaxel with a ferrocenoyl moiety, in particular, led to formation of an analogue that was at least one order of magnitude more potent in terms of antiproliferative activity than the parent compound (IC50values of 0.11 versus 1.11 μm, respectively), but still preserved the classical taxane mode of action, that is, microtubule stabilisation leading to mitotic arrest. Molecular docking studies revealed an unexpected binding pocket in the tubulin structure for the ferrocenoyl group introduced in the paclitaxel backbone.
- Wieczorek, Anna,B?au?, Andrzej,?al, Aleksandra,Arabshahi, Homayon John,Reynisson, Jóhannes,Hartinger, Christian G.,Rychlik, B?a?ej,Pla?uk, Damian
-
supporting information
p. 11413 - 11421
(2016/08/03)
-
- MULTI-ARM POLYMERIC PRODRUG CONJUGATES OF TAXANE-BASED COMPOUNDS
-
Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of taxane-based compounds and/or fluorinated forms thereof. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the taxane-based compound is achieved.
- -
-
Paragraph 0228; 0229
(2016/09/12)
-
- TAXANE COMPOUND, AND PREPARATION METHOD AND USE THEREOF
-
Provided are taxanes compounds having the structure of formula I, preparation method thereof, and uses of compositions having the compound, pharmaceutical salts and solvates thereof as active ingredients in the preparation of oral antitumor drugs. In the formula, R1 is —COR6, —COOR6, and —CONR7aR7b; R2 is C1-C6 alkyl, C1-C6 alkenyl group, a substituted hydrocarbon group, a heterocyclic group, an aromatic group or a substituted aromatic group; R3 is —OR6, —OCOOR6, —OCOSR6, and —OCONR7aR7b; R4 is —OR6, —OCOOR6, —OCOSR6, —OCONR7aR7b, H, and OH; R6 is C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl group, a substituted hydrocarbon group, an aromatic group or a heterocyclic group; and R7a and R7b are respectively hydrogen, a hydrocarbon group, a substituted hydrocarbon group or a heterocyclic group.
- -
-
Paragraph 0196; 0197; 0203; 0212; 0230; 0271; 0288; 0305
(2016/12/16)
-
- Taxanes Compounds, Preparation Method Therefor, and Uses Thereof
-
The present invention provides taxanes compounds with a formula (I) or formula (II) structure, a method for preparing the compounds, as well as the use of the compositions containing the compounds, pharmaceutically acceptable salts and solvates thereof as active ingredients in manufacturing oral antitumor medicaments, In formula (I), R1 is —COR6, —COOR6 or —CONR7aR7b; R2 is a C1-C6 alkyl, a C1-C6 alkenyl, a substituted hydrocarbon group, a heterocyclic group, an aromatic group or a substituted aromatic group; R3 is —OR6, —OCOOR6, —OCOSR6 or —OCONR7aR7b; R4 is —OR6, —OCOOR6, —OCOSR6, —OCONR7aR7b or H; wherein, R6 is a C1-C6 alkyl, a C1-C6 alkenyl, a C1-C6 alkynyl, a substituted hydrocarbon group, an aromatic group or a heterocyclic group; R7a and R7b are respectively hydrogen, a hydrocarbon group, a substituted hydrocarbon group or a heterocyclic group. In formula (II), R1 is —COR6 or —COOR6; R2 is an aromatic group; R3 is —OR6; wherein, R6 is a C1-C6 alkyl, a C1-C6 alkenyl, a C1-C6 alkynyl, a substituted hydrocarbon group, an aromatic group or a heterocyclic group.
- -
-
Paragraph 0167; 0209; 249; 0262, 0307, 0380
(2016/10/31)
-
- PROCESS FOR THE PREPARATION OF CABAZITAXEL AND ITS SOLVATES
-
The present disclosure provides anisole and benzyl alcohol solvates of cabazitaxel and methods of their production. The solvates may be characterized by powder x-ray diffraction patterns. The present disclosure also provides methods for the synthesis of cabazitaxel.
- -
-
Page/Page column 11
(2015/06/25)
-
- NOVEL METHOD FOR PREPARING CABAZITAXEL FROM 10-DEACETYLBACCATIN III IN HIGH YIELD, AND NOVEL INTERMEDIATE THEREFOR
-
The present invention relates to a novel method for preparing cabazitaxel from 10-deacetylbaccatin III, and a novel intermediate therefor, and more specifically, to: a method which allows cabazitaxel to be more easily prepared in a high yield and in a high purity within a short time compared with a conventional method by preparing cabazitaxel via a novel intermediate using 10-deacetylbaccatin III as a starting material, and thus is suitable for industrial mass production; and a novel intermediate therefor.
- -
-
Paragraph 0011; 0050
(2015/11/03)
-
- PROCESS FOR THE PREPARATION CABAZITAXEL
-
The present invention discloses a process for the preparation of 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1-hydroxy-7β,10β-dimethoxy-9-oxotax-11-en-13α-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate Cabazitaxel (I).
- -
-
Paragraph 0083-0085
(2014/03/24)
-
- The synthesis of novel taxoids for oral administration
-
A group of novel taxoids, with modifications at C-7, C-10, C-3′ and C-14 positions of paclitaxel, was synthesized in order to improve their biological profile by decreasing their affinity with P-glycoprotein (P-gp) and increasing cellular permeability. Most of the new taxoids demonstrated the similar potent cytotoxic activities in MCF-7 human tumor cell line as paclitaxel in vitro. In the permeability assay with monolayers of Caco-2 cells, most of the compounds demonstrated an increased trans-cellular transport in A-to-B direction in comparison with paclitaxel. Among them the compounds T-13, T-15 and T-26 showed the highest permeability, and with efflux ratios better than that of ortataxel. The interaction of the compounds T-13 and T-26 with P-gp was evaluated using Madin-Darby canine kidney (MDCK)-multidrug resistance-1(MDR1) and MDCK-wild-type (WT). The results indicated that T-13 and T-26 were poor substrates for P-gp and possessed inhibiting effects of P-gp mediated efflux. It was thus clear that simultaneous modifications at the C-7, C-10 and C-3′ positions of paclitaxel significantly impaired its interactions with P-gp and interfered with P-gp mediated efflux.
- Jing, Yun-Rong,Zhou, Wei,Li, Wan-Liang,Zhao, Lin-Xiang,Wang, Yong-Feng
-
p. 194 - 203
(2014/01/17)
-
- PROCESS FOR MAKING AN INTERMEDIATE OF CABAZITAXEL
-
A novel process of making 7,10-dialkyl-10-DAB of formula (I) which is useful as a key intermediate for the preparation of cabazitaxel, comprises selective elaboration of positions 7 and 10 of 10-deacetylbaccatin III.
- -
-
Paragraph 0040-0041
(2013/04/13)
-
- PROCESS FOR CABAZITAXEL, AND INTERMEDIATES THEREOF
-
The present invention relates to processes for making cabazitaxel, cabazitaxel analogues and intermediates thereof. The invention provides novel compounds useful in the synthesis of cabazitaxel.
- -
-
Paragraph 0177
(2013/05/21)
-
- PROCESSES FOR THE PREPARATION OF CABAZITAXEL INVOLVING C(7) -OH AND C(13) -OH SILYLATION OR JUST C(7) -OH SILYLATION
-
Disclosed are processes towards Cabazitaxel (I) starting from 10-Deacetylbaccatin (III) that involve steps of either 7-OH monosilylation (passing through formula V) or 7,13-disilylation (passing through formulae XI, XII). Isopropanol Solvates of Cabazitaxel and processes to make this are also described.
- -
-
Page/Page column 16; 17
(2013/05/23)
-
- NON-RING HYDROXY SUBSTITUTED TAXANES AND METHODS FOR SYNTHESIZING THE SAME
-
The invention relates to (among other things) non-ring hydroxy substituted taxanes and methods for synthesizing the same. The invention further relates to conjugating the non-ring hydroxyl substituted taxanes to a water-soluble, non-peptidic polymer.
- -
-
Page/Page column 30-31
(2012/07/13)
-
- DEUTERATED AND/OR FLUORINATED TAXANE DERIVATIVES
-
The invention relates to (among other things) deuterated and/or fluorinated docetaxel and cabazitaxel and derivatives thereof, as well as compositions comprising each of the foregoing.
- -
-
Page/Page column 43
(2012/07/13)
-
- Design, synthesis, and biological evaluation of new-generation taxoids
-
Novel second-generation taxoids with systematic modifications at the C2, C10, and C3′N positions were synthesized and their structure-activity relationships studied. A number of these taxoids exhibited exceptionally high potency against multidrug-resistan
- Ojima, Iwao,Chen, Jin,Sun, Liang,Borella, Christopher P.,Wang, Tao,Miller, Michael L.,Lin, Songnian,Geng, Xudong,Kuznetsova, Larisa,Qu, Chuanxing,Gallager, David,Zhao, Xianrui,Zanardi, Ilaria,Xia, Shujun,Horwitz, Susan B.,Mallen-St. Clair, Jon,Guerriero, Jennifer L.,Bar-Sagi, Dafna,Veith, Jean M.,Pera, Paula,Bernacki, Ralph J.
-
scheme or table
p. 3203 - 3221
(2009/05/11)
-
- SEMI-SYNTHETIC ROUTE FOR THE PREPARATION OF PACLITAXEL, DOCETAXEL, AND 10-DEACETYLBACCATIN III FROM 9-DIHYDRO-13-ACETYLBACCATIN III
-
A novel semisynthetic route has been provided in the preparation of docetaxel and paclitaxel. This new process involves the conversion of 9-dihydro-13-acetylbaccatinIII to docetaxel and paclitaxel by the step of converting 9-dihydro-13-acetylbaccatin III into 7-O-triethylsilyl-9,10-diketobaccatin III, and adding docetaxel and paclitaxel side chain precursors, respectively, to form a new class of taxane intermediates, such as 7-O-triethylsilyl-9,10-diketodocetaxel and 7-O-triethylsilyl-9,10-diketopaclitaxeltaxel. These new intermediates then by a series reduction, acetylation of the 10-hydroxyl position for paclitaxel and finally deprotection to yield docetaxel and paclitaxel, the most important anti-cancer drugs.
- -
-
Page/Page column 7
(2008/06/13)
-
- C10 cyclopropyl ester substituted taxane compositions
-
Compositions comprising a taxane having a cyclopropyl ester substituent at C10, a keto substituent at C9, a hydroxy substituent at C7, a 2-furyl substituent at C3′ and an isobutoxycarbamate substituent at C3′.
- -
-
Page/Page column 7
(2008/06/13)
-
- C10 cyclopentyl ester substituted taxanes
-
A taxane having a cyclopentyl ester substituent at C10, a keto substituent at C9, a hydroxy substituent at C2, a 2-thienyl substituent at C3′ and an isopropoxycarbamate substituent at C3′.
- -
-
Page/Page column 6-7
(2008/06/13)
-
- Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents
-
A series of novel taxane-based multidrug resistance (MDR) reversal agents (TRAs) has been designed and synthesized. Structure - activity relationship (SAR) study clearly indicates that modification of the C-7 position with hydrophobic arenecarbonylcinnamoyl groups brings about high potency against drug efflux mediated by P-glycoprotein (P-gp). Six TRAs exhibit ability to modulate a wide range of ATP-binding cassette (ABC) transporters, such as P-gp, multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein (BCRP), which may serve as novel broad-spectrum modulators of ABC transporters.
- Ojima, Iwao,Borella, Christopher P.,Wu, Xinyuan,Bounaud, Pierre-Yves,Oderda, Cecilia Fumero,Sturm, Matthew,Miller, Michael L.,Chakravarty, Subrata,Chen, Jin,Huang, Qing,Pera, Paula,Brooks, Tracy A.,Baer, Maria R.,Bernacki, Ralph J.
-
p. 2218 - 2228
(2007/10/03)
-
- Facile method for synthesizing baccatin III compounds
-
A process for synthesizing a C-7 protected baccatin III compound represented by formula (A), which comprises reacting a 10-deacetylbaccatin III compound represented by formula (B) with a protecting agent and an acylating agent in the presence of a secondary amine and a nitrogen-containing compound. Also, a process for synthesizing a C-7 protected 10-deacetylbaccatin III compound represented by formula (C), which comprises reacting a 10-deacetylbaccatin III compound represented by formula (B) with a protecting agent in the presence of a secondary amine and a nitrogen-containing compound. In both processes the nitrogen-containing compound is selected from a nitrogen-containing heterocycle or a trialkylamine. When the nitrogen-containing heterocycle is selected, it may be an unsubstituted or a substituted pyridine or an unsubstituted or a substituted pyrazine. When a trialkylamine is selected, it may be, for example, triethylamine or diisopropylethylamine. wherein PG1 represents the organic residue of the protecting agent, PG2 represents the organic residue of the acylating agent, and R represents a simple or substituted aryl group or a heterocyclic group.
- -
-
-
- Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups
-
Process for the preparation of a derivative or analog of baccatin III or 10-desacetyl baccatin III having a C2 substituent other than benzoate and/or a C4 substituent other than acetate in which the C2 benzoate substituent and/or the C4 acetate substituen
- -
-
Page column 38 - 39
(2010/02/06)
-
- Structure-activity relationship study of taxoids for their ability to activate murine macrophages as well as inhibit the growth of macrophage-like cells
-
A series of new taxoids modified at the C-3′, C-3′N, C-10, C-2 and C-7 positions has been designed, synthesized and evaluated for their potency to induce NO and TNF production by peritoneal murine macrophages (Mφ) from LPS-responsive C3H/HeN and LPS-hyporesponsive C3H/HeJ strains and human blood cells, and for their ability to inhibit the growth of Mφ-like cell lines J774.1 and J7.DEF3. The SAR-study has shown that the nature of the substituents at these positions have critical effect on the induction of TNF and NO production by Mφ. Positions C-3′ and C-10 are the most flexible and an intriguing effect of the length of the substituents at the C-10 position is observed for taxoids bearing a straight chain alkanoyl moiety. An aromatic group at the C-3′N and C-2 positions is required for the activity, while only hydroxyl or acetyl substituents seem to be tolerated at the C-7 position. The natural stereochemistry in the C-13 isoserine side chain of the taxoids is an absolute requirement for macrophage activation. It has also been clearly shown that there is no correlation between the ability of the taxoids to induce TNF/NO production in C3H/HeN Mφ and the cytotoxicity against Mφ-like cells.
- Ojima, Iwao,Fumero-Oderda, Cecilia L.,Kuduk, Scott D.,Ma, Zhuping,Kirikae, Fumiko,Kirikae, Teruo
-
p. 2867 - 2888
(2007/10/03)
-
- Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them
-
Taxane derivatives having an alkyl substituted C13 side chain.
- -
-
Page column 8
(2010/01/30)
-
- Beta-Lactams useful for preparation of substituted isoserine esters using metal alkoxides
-
β-lactams are disclosed which are useful for preparing N-acyl, N-sulfonyl and N-phosphoryl substituted esters by reaction with a metal alkoxide.
- -
-
-
- C2 substituted phenyl taxane derivatives and pharmaceutical compositions containing them
-
Taxane derivatives having alternative C2 substituents.
- -
-
Page column 17-18
(2010/01/30)
-
- C13 amido substituted taxane derivatives and pharmaceutical compositions containing them
-
Taxane derivatives having an amino substituted C13 side chain.
- -
-
Page column 17-18
(2010/01/31)
-
- New photoaffinity analogs of paclitaxel
-
Two new photoreactive paclitaxel analogs bearing [3H2]-3-(4- benzoyl)phenylpropanoyl group as the photophore as well as radiolabeling unit at the 7 and 10 positions, respectively, are developed. These new photoreactive analogs showed
- Ojima, Iwao,Bounaud, Pierre-Yves,Ahern, David G.
-
p. 1189 - 1194
(2007/10/03)
-
- New taxanes as highly efficient reversal agents for multidrug resistance in cancer cells
-
New non-cytotoxic taxanes synthesized from 10-deacetylbaccatin III and special hydrophobic acylating agents show remarkable MDR reversal activity (≤99.8%) against drug-resistant human breast cancer cells when co-administered with paclitaxel or doxorubicin. This activity is ascribed to the highly efficient blocking of P-glycoprotein efflux by these new taxanes.
- Ojima, Iwao,Bounaud, Pierre-Yves,Takeuchi, Craig,Pera, Paula,Bernacki, Ralph J.
-
p. 189 - 194
(2007/10/03)
-
- Chemical synthesis and biological evaluation of C-2 taxoids
-
An efficient, general method for the synthesis of 1,2-hydroxy esters by regioselective nucleophilic opening of 1,2-cyclic carbonate systems has been developed. A reliable and practical route giving access to the taxoid carbonate 2 from the readily availab
- Nicolaou,Renaud,Nantermet,Couladouros,Guy,Wrasidlo
-
p. 2409 - 2420
(2007/10/02)
-
- The Chemistry of Taxanes: Skeletal Rearrangements of Baccatin Derivatives via Radical Intermediates
-
In the course of a synthetic program aimed at systematic defunctionalization of the taxol core for structure activity studies, a number of radical-based deoxygenation reactions were carried out on baccatin III derivatives.In this connection, we have discovered that formation of radicals at positions C-1, C-2, and C-7 in the taxane core of baccatin III results in a number of skeletal rearrangement cascades.Furthermore, the exact composition of the product mixture depends on the specific tin (or silicon) hydride used for the reduction.In the case of C-2 and C-7-derived radicals, direct quenching with tin hydrides without rearrangement was possible under some conditions.However, we were unable to find conditions to quench the C-1 radical, since rearrangement pathways always predominate in this case.
- Chen, Shu-Hui,Huang, Stella,Gao, Qi,Golik, Jerzy,Farina, Vittorio
-
p. 1475 - 1484
(2007/10/02)
-
- Synthesis of 10-deacetoxytaxol and 10-deoxytaxotere
-
10-Deacetoxytaxol (9) and 10-deoxytaxotere (10) have been prepared from 10-deacetylbaccatin III by attachment of the C-13 side-chain and deoxygenation. 10-Deacetoxytaxol is comparable to taxol in its cytotoxicity to P-388 cells, but 10-deoxytaxotere is si
- Chaudhary,Kingston
-
p. 4921 - 4924
(2007/10/02)
-